A study published in July 2020 hypothesized a link between bradykinin, a well-known peptide, and severe cases of COVID-19. TTUHSC's Vardan Karamyan, Ph.D., found the article intriguing because it discussed bradykinin, one of three specific peptides with which his lab has much experience. In a focused review published in March by Physiological Reports, Karamyan suggests two other bioactive peptides also may be involved in the same processes and mechanisms proposed in the original paper.
To clarify the origins of coronavirus' infections in humans, researchers from the Bioinformatics Research Center (BRC) at the University of North Carolina at Charlotte (UNC Charlotte) performed the most comprehensive evolutionary analyses of these viruses to date. The UNC Charlotte team analyzed over 2,000 genomes of diverse coronaviruses that infect humans or other animals.
A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) treated with a heparin alternative following the Centers for Disease Control and Prevention (CDC) guidance.
If a respiratory droplet from a person infected with COVID-19 lands on a surface, it becomes a possible source of disease spread, because while 99.9% of the droplet's liquid content evaporates within minutes, a residual thin film that allows the virus to survive can be left behind. In Physics of Fluids, researchers explore how the evaporation rate of residual thin films can be accelerated by tuning surfaces' wettability and creating geometric microtextures on them.
University of New Mexico Researchers Create Open Source Computational Tool to Rapidly Screen Molecules For COVID-Fighting Properties.
A Wyss Institute-led collaboration spanning four research institutions has used the Institute's Organ Chip technology to identify the antimalarial drug amodiaquine as a potent inhibitor of infection with SARS-CoV-2, the virus that causes COVID-19. This research contributed to the inclusion of amodiaquine in ongoing COVID-19 human clinical trials in Africa, where the drug is widely available, and can be used to address future pandemics.
An influenza vaccine that is made of nanoparticles and administered through the nose enhances the body's immune response to influenza virus infection and offers broad protection against different viral strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.
A Phase II trial at MD Anderson tound that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.
Scientists from several hospitals and research centers have shown what happens in the tissues of patients who died of COVID-19. In a study published in Nature, the researchers describe how infected cells from multiple organs exhibited a range of molecular and genomic changes. They also saw signs of multiple, unsuccessful attempts by the lungs to repair themselves in response to respiratory failure -- the leading cause of death in COVID-19 patients.
The United Kingdom government plans to implement mass scale population testing for SARS-CoV-2 infection using Lateral Flow Devices (LFDs), yet the devices' sensitivity is unknown. A study published in the open access journal PLOS Biology by Alan McNally at University of Birmingham, UK, and colleagues suggests while LFDs are highly effective in identifying SARS-CoV-2 in individuals with high quantities of viral RNA present on the test swab, they are inaccurate at diagnosing infections in individuals with lower viral loads.